Back to Search
Start Over
Bevacizumab in recurrent high-grade glioma: a single institution retrospective analysis on 92 patients.
- Source :
-
La Radiologia medica [Radiol Med] 2021 Sep; Vol. 126 (9), pp. 1249-1254. Date of Electronic Publication: 2021 Jun 03. - Publication Year :
- 2021
-
Abstract
- Background: High-grade gliomas are among the most aggressive central nervous system primary tumors, with a high risk of recurrence and a poor prognosis. Re-operation, re-irradiation, chemotherapy are options in this setting. No-best therapy has been established. Bevacizumab was approved on the basis of two Phase 2 trials that evaluated its efficacy in patients with recurrent glioblastoma.<br />Materials and Methods: We have retrospectively review data of patients with high-grade glioma treated at our institution that undergone radiological or histological progression after at least one systemic treatment for recurrent disease. Bevacizumab was administered alone or in combination with chemotherapy until disease progression or unacceptable toxicity. Bevacizumab regimen was analyzed to assess PFS and OS. Histological, molecular and clinical features of the entire cohort were collected.<br />Results: We reviewed data from 92 patients, treated from April 2009 to November 2019, with histologically confirmed diagnosis of high-grade gliomas and recurrent disease. A PFS of 55.2%, 22.9% and 9.6% was observed at 6, 12 and 24 months, respectively. Performance status, age at diagnosis (< 65 or > 65 ys.) and use of corticosteroids during bevacizumab therapy were strongly associated with PFS. The OS was 74.9% at 6 months, 31.7% at 12 months, 10.1% at 24 months. In our cohort, 51.1% were long-term responders (PFS > 6 months). Globally, bevacizumab treatment was well tolerated.<br />Conclusion: Our analysis confirms the efficacy of bevacizumab in recurrent high-grade glioma patients with an acceptable toxicity profile, in keeping with its known safety in the literature.<br /> (© 2021. The Author(s).)
- Subjects :
- Adult
Aged
Antineoplastic Agents, Immunological adverse effects
Antineoplastic Combined Chemotherapy Protocols therapeutic use
Bevacizumab adverse effects
Brain Neoplasms mortality
Brain Neoplasms pathology
Brain Neoplasms surgery
Female
Glioblastoma drug therapy
Glioblastoma mortality
Glioblastoma pathology
Glioma mortality
Glioma pathology
Glioma surgery
Humans
Male
Middle Aged
Neoplasm Grading
Retrospective Studies
Survival Analysis
Antineoplastic Agents, Immunological therapeutic use
Bevacizumab therapeutic use
Brain Neoplasms drug therapy
Glioma drug therapy
Neoplasm Recurrence, Local drug therapy
Subjects
Details
- Language :
- English
- ISSN :
- 1826-6983
- Volume :
- 126
- Issue :
- 9
- Database :
- MEDLINE
- Journal :
- La Radiologia medica
- Publication Type :
- Academic Journal
- Accession number :
- 34081269
- Full Text :
- https://doi.org/10.1007/s11547-021-01381-5